Alpha-Deoxyguanosine to Reshape the Alpha-Thrombin Binding Aptamer

被引:1
|
作者
Kolganova, Natalia A. [1 ]
Tsvetkov, Vladimir B. [2 ,3 ,4 ]
Stomakhin, Andrey A. [1 ]
Surzhikov, Sergei A. [1 ]
Timofeev, Edward N. [1 ]
Varizhuk, Irina V. [1 ]
机构
[1] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia
[2] Fed Res & Clin Ctr Phys Chem Med, Moscow 119435, Russia
[3] Sechenov First Moscow State Med Univ, Inst Biodesign & Complex Syst Modeling, Moscow 119146, Russia
[4] AV Topchiev Inst Petrochem Synth, Russian Acad Sci, Moscow 119991, Russia
关键词
alpha-thrombin; aptamer; G-quadruplex; alpha-deoxyguanosine; peptide-oligonucleotide conjugate; circular dichroism; anticoagulant activity; molecular dynamics; DNA; QUADRUPLEX; EPSILON; DUPLEX;
D O I
10.3390/ijms24098406
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Modification of DNA aptamers is aimed at increasing their thermodynamic stability, and improving affinity and resistance to biodegradation. G-quadruplex DNA aptamers are a family of affinity ligands that form non-canonical DNA assemblies based on a G-tetrads stack. Modification of the quadruplex core is challenging since it can cause complete loss of affinity of the aptamer. On the other hand, increased thermodynamic stability could be a worthy reward. In the current paper, we developed new three- and four-layer modified analogues of the thrombin binding aptamer with high thermal stability, which retain anticoagulant activity against alpha-thrombin. In the modified aptamers, one or two G-tetrads contained non-natural anti-preferred alpha-deoxyguanosines at specific positions. The use of this nucleotide analogue made it possible to control the topology of the modified structures. Due to the presence of non-natural tetrads, we observed some decrease in the anticoagulant activity of the modified aptamers compared to the natural prototype. This negative effect was completely compensated by conjugation of the aptamers with optimized tripeptide sequences.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Bradykinin antagonizes the effects of alpha-thrombin
    Ehringer, WD
    Edwards, MJ
    Gray, RD
    Miller, FN
    INFLAMMATION, 1997, 21 (03) : 279 - 298
  • [22] CONFORMATIONAL TRANSITIONS IN HUMAN ALPHA-THROMBIN
    DECRISTOFARO, R
    DECANDIA, E
    PICOZZI, M
    BIZZI, B
    LANDOLFI, R
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 925 - 925
  • [23] INTERACTION OF HUMAN ALPHA-ANTITRYPSIN AND HUMAN ALPHA-THROMBIN
    DOWNING, MR
    TAYLOR, JC
    MANN, KG
    BLOOD, 1976, 48 (06) : 975 - 975
  • [24] HUMAN ALPHA-THROMBIN BINDING TO NONPOLYMERIZED FIBRIN SEPHAROSE - EVIDENCE FOR AN ANIONIC BINDING REGION
    BERLINER, LJ
    SUGAWARA, Y
    FENTON, JW
    BIOCHEMISTRY, 1985, 24 (24) : 7005 - 7009
  • [25] HIGH-AFFINITY ALPHA-THROMBIN BINDING TO PLATELET GLYCOPROTEIN-IB-ALPHA - IDENTIFICATION OF 2 BINDING DOMAINS
    GRALNICK, HR
    WILLIAMS, S
    MCKEOWN, LP
    HANSMANN, K
    FENTON, JW
    KRUTZSCH, H
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) : 6334 - 6338
  • [26] THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED-DNA APTAMER
    PADMANABHAN, K
    PADMANABHAN, KP
    FERRARA, JD
    SADLER, JE
    TULINSKY, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (24) : 17651 - 17654
  • [27] MOLECULAR ANALYSIS OF THE INTERACTION OF HIRUDIN AND ALPHA-THROMBIN
    PILAT, MJP
    DOSCHER, MS
    FEDERATION PROCEEDINGS, 1986, 45 (06) : 1494 - 1494
  • [28] FIBRIN(OGEN) RECOGNITION INVOLVING THE ANION-BINDING EXOSITE IN ALPHA-THROMBIN
    FENTON, JW
    WILNER, GD
    BIOCHEMISTRY, BIOLOGICAL FUNCTIONS, GENE REGULATION AND EXPRESSION, 1988, 801 : 53 - 58
  • [29] STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
    TABERNERO, L
    CHANG, CYY
    OHRINGER, SL
    LAU, WF
    IWANOWICZ, EJ
    HAN, WC
    WANG, TC
    SEILER, SM
    ROBERTS, DGM
    SACK, JS
    JOURNAL OF MOLECULAR BIOLOGY, 1995, 246 (01) : 14 - 20
  • [30] INVIVO METABOLISM OF REVERSIBLY INHIBITED ALPHA-THROMBIN
    SHIFMAN, MA
    PIZZO, SV
    BIOCHEMICAL PHARMACOLOGY, 1983, 32 (04) : 739 - 741